Novartis (SWX:NOVN) has signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset.
The deal gives Novartis worldwide rights to develop and commercialise the BoomRay program as part of its radiopharmaceutical pipeline.
The agreement adds another early stage oncology candidate to Novartis’ radioligand therapy efforts, expanding its presence in targeted cancer treatments.
This new BoomRay radioligand license sits within a wider pattern our research has traced across Novartis’ cancer drug efforts. Our analysis turns up 1 warning sign for Novartis as well.
For readers tracking how large pharma is repositioning around precision oncology and AI-enabled drug discovery, it is worth scanning 134 healthcare AI stocks.
SWX:NOVN Earnings & Revenue Growth as at Sep 2026
Novartis is a CHF223.5 billion pharmaceuticals group that researches, develops, manufactures, and sells medicines worldwide, so expanding radiopharmaceuticals fits directly into its broader oncology drug portfolio rather than sitting as a one off experiment on the side.
3 things going right for Novartis that this headline doesn’t cover.
Novartis leans harder into radioligand therapies, but with preclinical risk attached
For Novartis, this BoomRay license leans into the Narrative that advanced therapies and complex oncology platforms can support future earnings power, rather than being a side project. It lines up with the view that a broad, technically demanding pipeline in areas like radioligand therapy can help offset pressures from patent expiries and tougher pricing, even if each early program carries clear scientific and regulatory uncertainty.
See how these catalysts shape Novartis’ path to a CHF126 fair value.
The most useful early proof point is not revenue, but clinical progress. Investors can monitor whether Novartis moves this BoomRay asset into first in human studies, secures an initial safety readout, and then discloses whether it sees enough signal to prioritize it against other oncology projects in its RLT portfolio.
Add Novartis to your Watchlist and get alerts as these catalysts play out.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com